Chong Kun Dang introduced on Dec. 3 that it introduced preclinical analysis outcomes for its degenerative neurological illness therapy candidate ‘CKD-513’ on the ‘2025 Society for Neuroscience Annual Assembly’ not too long ago held in California, United States.
CKD-513 selectively inhibits HDAC6, an enzyme that disrupts materials transport inside axons by decreasing the steadiness of microtubules inside nerve cells. It’s a therapy candidate with a novel mechanism that instantly improves nerve cell operate by restoring microtubule stability and axonal transport. The drug is evaluated as having overcome the restrictions of current HDAC6 inhibitors by considerably enhancing drug penetration into the mind. Leveraging these traits, Chong Kun Dang is creating remedies focusing on degenerative neurological illnesses resembling Alzheimer’s dementia, tauopathy, and Charcot-Marie-Tooth (CMT) illness.
On this presentation, the corporate disclosed efficacy outcomes from a tauopathy mannequin, a degenerative central nervous system illness. Tauopathy is a degenerative mind illness by which tau proteins abnormally accumulate in mind nerve cells, resulting in deteriorated nerve cell operate, and is named a significant trigger of assorted neurological illnesses together with Alzheimer’s dementia.
Preclinical analysis outcomes confirmed that CKD-513 secured excessive selectivity for HDAC6 and wonderful mind penetration, and restored broken axonal transport to regular ranges in tau protein-overexpressing cells and illness animal fashions. The examine confirmed cognitive operate and reminiscence restoration results within the illness animal fashions, and long-term potentiation (LTP) analysis outcomes additionally proved nerve cell operate enchancment.
A Chong Kun Dang consultant acknowledged, “This presentation is a significant achievement that demonstrates the brand new prospects of Chong Kun Dang’s proprietary HDAC6 inhibition platform expertise,” including, “Primarily based on the nerve cell operate enchancment results confirmed in tauopathy and Charcot-Marie-Tooth illness fashions, we’ll additional speed up analysis and growth within the subject of neurological illnesses.”
In response to Chong Kun Dang, CKD-513 was not too long ago chosen for a nationwide undertaking by the Korea Drug Improvement Fund (KDDF) and can obtain assist for preclinical analysis. The aim is to enter Part 1 medical trials by the tip of subsequent 12 months. The Nationwide New Drug Improvement Undertaking is a pan-government nationwide analysis and growth (R&D) initiative to strengthen the worldwide competitiveness of the pharmaceutical and biotechnology industries, supporting all the lifecycle levels of latest drug growth from 2021 for 10 years with targets of strengthening the home new drug growth R&D ecosystem, creating international commercialization outcomes, and producing public curiosity achievements within the healthcare and medical fields.
